Trial Profile

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2023 Results of pooled analysis from STEP 1 and STEP 2 presented at the European Association for the Study of the Liver Congress 2023
01 Dec 2022 Results assessing the safety and efficacy of a weekly 2.4-mg subcutaneous injection of semaglutide for chronic weight management in STEPS 1-4 studies, published in the American Journal of Managed Care.
23 Sep 2022 Results assessing the relationship between body weight loss and glycaemiccontrol in participants with overweight/obesity and T2D receiving semag-lutide pharmacotherapy, esented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com